Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Hosted on MSN11h
Eli Lilly: 4 Reasons Investors Shouldn't Miss This OpportunityEli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...
Hosted on MSN22h
Pharma Market Forecast: Top Trends for Pharma in 2025The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...
Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...
Kroger settles an opioid lawsuit in Kentucky for $110 million. The U.S. builds a bird flu vaccine stockpile. Shanghai permits ...
Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...
The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback